|Bid||1.2700 x 800|
|Ask||1.2800 x 900|
|Day's Range||1.2700 - 1.3150|
|52 Week Range||0.4100 - 3.9000|
|Beta (5Y Monthly)||3.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced the Centers for Medicare and Medicaid Services ("CMS") issued Healthcare Common Procedure Coding System ("HCPCS") Level II Code K1007 in response to the Company's application. This decision, which will be effective on October 1, 2020, establishes the first such code for exoskeletons.
ReWalk also issued unregistered warrants to purchase up to an aggregate amount of 2,469,139 ordinary shares. The warrants have a term of five and one-half years, are exercisable immediately following the issuance date and have an exercise price of $1.76 per ordinary share.
ReWalk has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate amount of 2,469,139 ordinary shares. The warrants will have a term of five and one-half years, be exercisable immediately following the issuance date and have an exercise price of $1.76 per ordinary share. The Company intends to use the net proceeds from the offering for the following purposes: (i) sales, marketing and reimbursement expenses related to market development activities of the Company’s ReStore device, broadening third-party payor coverage for the ReWalk Personal device and commercializing its new product lines added through distribution agreements; (ii) research and development costs related to the Company’s products maintenance, as well as developing its lightweight exo-suit technology for potential home rehab with tele-heath features.